Your browser doesn't support javascript.
loading
Sortilin, carbamylation, and cardiovascular calcification in chronic kidney disease.
Massy, Ziad A; Liabeuf, Sophie.
Afiliação
  • Massy ZA; Department of Nephrology, Ambroise Paré University Medical Center, Assistance Publique - Hôpitaux de Paris, Boulogne-Billancourt/Paris, France; Inserm 1018 Team5, Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Inserm, Clinical Epidemiology Team, Centre de Recherche en Epidémiologie et Santé des Populations, Villejuif, France. Electronic address: ziad.massy@aphp.fr.
  • Liabeuf S; Pharmacology Department, Amiens University Medical Center, Amiens, France; Research Unit, MP3CV Laboratory, EA7517, University of Picardie Jules Verne, Amiens, France.
Kidney Int ; 101(3): 456-459, 2022 03.
Article em En | MEDLINE | ID: mdl-35190032
ABSTRACT
Sortilin appears to play important roles in the pathogenesis of vascular and metabolic diseases, such as cardiovascular calcification. Post-translational modifications of sortilin (i.e., phosphorylation or carbamylation) are among the key mechanisms of its actions. Recent data extended the role of carbamylated sortilin to the pathogenesis of cardiovascular calcifications in chronic kidney disease. Whether therapeutic tools potentially available to inhibit the carbamylation process in chronic kidney disease patients would allow preventing cardiovascular calcifications remains to be demonstrated.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Carbamilação de Proteínas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Carbamilação de Proteínas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article